Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
about
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.Safety and tolerability of putaminal AADC gene therapy for Parkinson diseasePurification of functional baculovirus particles from silkworm larval hemolymph and their use as nanoparticles for the detection of human prorenin receptor (PRR) binding.Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectorsCharacterization of a recombinant adeno-associated virus type 2 Reference Standard MaterialSystemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liverInterventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's diseaseAdeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdalaA nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculationSafety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates.The state of the art of adeno-associated virus-based vectors in gene therapy.A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapyEfficient gene therapy-based method for the delivery of therapeutics to primate cortex.A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.Real-time MR imaging of adeno-associated viral vector delivery to the primate brain.Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain.Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indicationsAAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations.Anterograde axonal transport of AAV2-GDNF in rat basal gangliaGene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences.Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders.
P2860
Q30531601-424A36BB-4E5C-493A-B6CE-54F3D2BD7F39Q33731687-0A7EB767-5222-4829-8E22-917201930F3BQ33920192-8DA13CFA-4B4A-4CAF-AC90-E2F9A16A0049Q34039452-580CFE0A-7D33-4B51-94DF-BE5548869AAAQ34080874-F7C0B05B-B4D4-4517-B0D2-D700FC6A58FDQ34211507-FF887C82-B90A-4931-A348-CF56EBA9A313Q34843835-63DC3242-F03E-4CAB-81AF-077E09BAA09CQ35086686-8D294CF6-7E6A-49B1-BADB-2C07AFD35B29Q35095825-6DCD7105-976C-4628-92A6-60F7F16F9D73Q35543174-C7E333C1-CACB-44BE-A149-280E48706BF8Q35751582-C9454DAD-55C4-410F-8C8B-2D676E308273Q36848703-AAE319B6-871F-488D-9CA1-CC47B16383BDQ36972714-8517FB74-863B-496B-9574-2262F8031579Q37012949-813ADF38-1C1A-4995-AFF4-D891BBFEE642Q37114888-B46D0EF6-FECE-453F-9935-FA9B720387EBQ37300994-52B8AA46-8453-41AF-91EF-66AFCC13F691Q37300999-20979968-DBAB-4666-BE01-35D0A90CE3CCQ37301013-F12770FF-F6D5-423F-9A38-EC4068AC2FCAQ37313954-568C63EB-C8AF-4BF3-B341-E3D80843F959Q37374468-B015F0BC-4D16-46E9-8125-E6F5EE20264DQ37398172-16EF2566-CDFF-4921-81DC-36D496A4DE1EQ37399627-5A7B4EE5-4ECC-4DE6-8A1E-15707AE8DA9AQ37571781-5E9EB6EB-C802-42D2-BB27-464F944CB2A3Q37615161-5137DF85-9562-4CAA-B45A-D134DDDCB369Q38166648-638F363E-F697-447B-914D-999E9A4038EBQ38828004-23451FBD-E15F-441C-9DC3-9A09F9BE4E50Q39628466-585A2DE0-F488-4605-A661-0959B79580C2Q40257549-B5E9313E-26A7-4413-9A30-7B370474D478Q40258000-FA449A15-23DF-482B-A538-A60173E92432Q42428990-BF73816E-2EC0-493C-B535-D85E4F361CA7
P2860
Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Recombinant adeno-associated v ...... ies for a gene therapy vector.
@ast
Recombinant adeno-associated v ...... ies for a gene therapy vector.
@en
type
label
Recombinant adeno-associated v ...... ies for a gene therapy vector.
@ast
Recombinant adeno-associated v ...... ies for a gene therapy vector.
@en
prefLabel
Recombinant adeno-associated v ...... ies for a gene therapy vector.
@ast
Recombinant adeno-associated v ...... ies for a gene therapy vector.
@en
P2093
P1476
Recombinant adeno-associated v ...... gies for a gene therapy vector
@en
P2093
Chunlin Tang
J Fraser Wright
Jurg M Sommer
P304
P577
2003-03-01T00:00:00Z